Entering text into the input field will update the search result below

FDA OKs Abbott's next-gen defibrillators

Jul. 06, 2020 8:25 AM ETAbbott Laboratories (ABT)ABTBy: Douglas W. House, SA News Editor1 Comment
  • Abbott (NYSE:ABT) announces the FDA nod for its Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices.
  • The company says new features include a patient-preferred design without compromising battery life and MRI compatibility and a smartphone app for improved remote monitoring.
  • The Gallant system was CE Mark'd in February.
  • Shares up 1% premarket on light volume.

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

"It is estimated that as many as 6.1 million people in the United States battle cardiac arrhythmias, or abnormal heart rhythms,1 and ICDs are used to help reduce the risks of life-threatening arrhythmias."

I wouldn't doubt seeing higher numbers now that so many are working from home and not
getting even walking exercise -
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.